The invention relates to a mussel adhesive protein (MAP) and an application thereof in inhibiting catarrh, and specifically, to applications of a MAP or a product thereof in oral mucositis, rhinitis, otitis media, pharyngitis, laryngitis, bronchitis, esophagitis, gastritis, enteritis, cervicitis, endomyometritis, inflammation resulting from inhalation injury, and oral cavity cancer, nasopharyngeal cancer, carcinoma of middle ear, conjunctival cancer, laryngeal cancer, lung cancer, esophageal cancer, stomach cancer, bowel cancer, cervical cancer, endometrial cancer, and other cancers resulting from the inflammation. The MAP can inhibit symptoms such as flush, fever, swell, and pain owing to catarrh, facilitating healing, relieving itch and pain, and having broad applications in the fields of medicines, cosmetics, medical products, disinfection products, healthcare products, foods, and household goods.

JIANGYIN BENGT I. SAMUELSSON INSTITUTE OF LIFE SCIENCE CO., LTD.

Mussel adhesive protein product and use thereof for treating mucosal inflammation

Disclosed are compounds of Formula I useful in the treatment of cyclooxygenase mediated diseases such as pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries. ##STR1##

Merck Frosst Canada, Inc.

Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase

The invention relates to a method of developing a main proteinase SARS inhibitor. Human coronaviruses are major causes of upper respiratory tract illnesses in humans, in particular, the common cold. Recent investigations have shown that a novel coronavirus causes the Severe Acute Respiratory Syndrome (SARS), a disease that is characterized by high fever, malaise, rigor, headache, non-productive cough or dyspnea, which is rapidly spreading. Within the scope of the invention, based on the structural analysis of the binding mode of the SARS M.sup.pro enzyme, a group of prototype inhibitors is provided that acts as suitable drugs targeting a majority of viral infections of the respiratory tract, including SARS.

common cold/karščiavimas

Mussel adhesive protein product and use thereof for treating mucosal inflammation

Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase

Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu